You can also find information about how the guideline was developed, including details of the committee. NICE has produced tools and resources to help you put this guideline into practice. For general help and advice on putting NICE guidelines into practice, see resources to help you put NICE guidance into practice. Update information April 2023: In recommendations 1.3.12 and 1.4.4, we updated the information about when placental growth factor (PLGF)-based testing for pre-eclampsia should be carried out. This brings it in line with our diagnostics guidance on PLGF-based testing to help diagnose suspected preterm pre-eclampsia. June 2019: We have reviewed the evidence on the assessment of proteinuria and the treatment of women with chronic and gestational hypertension and pre-eclampsia, breastfeeding and advice on discharge. These recommendations are marked [2019]. We have also made some changes without an evidence review: Combined, updated and clarified advice throughout to make it simpler to follow. Updated advice on pre-eclampsia in line with the NICE guidelines on antenatal care and pre-term labour and birth. Amended dose information for aspirin use in pre-eclampsia in line with current national guidance. Updated advice on rest, exercise and work for women with pre-eclampsia in line with the NICE guideline on antenatal care. Expanded the advice on the risks of angiotensin-converting enzyme (ACE) inhibitors to treat hypertension in pregnancy. Expanded and amended the advice on chlorothiazide to thiazide and thiazide-like diuretics, because chlorothiazide is no longer widely used. Updated terminology used for various aspects of treatment in line with current practice. Updated the advice on when to offer planned early birth and action to take beforehand. Updated the advice on continuing antihypertensive treatment after birth, including treatment with methyldopa. Added cross references where suitable to NICE guidance on breastfeeding. 